News – Global Alzheimer’s Platform Foundation

News

Learn more about the latest in Alzeimer's disease research, including the Global Alzheimer's Platform Foundation’s® impact on Alzheimer's and clinical trials.
Filter through our news categories
Blog

The Invaluable Role of Caregivers

November 19, 2019
It’s fitting that November is National Alzheimer’s Disease Awareness Month and National Family Caregivers Month. Nearly half of all caregivers for older adults in the United States - family, friends and other unpaid caregivers – are caring for someone with Alzheimer’s disease (AD).   Caregivers are essential to those living with Alzheimer’s and contribute 18.5 billion hours of care valued at nearly $234 billion. Caregivers for people with Alzheimer’s dementia...
Blog

Focus on the Funding

October 31, 2019
The facts are staggering… every 65 seconds someone in the United States develops Alzheimer’s disease. It is the most expensive disease in America, with the total direct cost of treatment approaching $300 billion annually - greater than for cancer or heart disease. It is the only leading cause of death in the US that cannot be prevented, cured or even slowed. Yet funding to fuel the research and trials needed...
Press Releases

Citizen Scientists Move Researchers Closer to Alzheimer’s Cure

October 23, 2019
Three research volunteers given first ever national award for their essential role in combatting the greatest public health crisis for our society in this century Washington, DC (October 23, 2019) –  Today, the Global Alzheimer’s Platform Foundation® (GAP) honors three Citizen Scientists® in recognition of the indispensable role clinical trial volunteers play in the fight against Alzheimer’s disease. Alzheimer’s is a national public health crisis, with more than 5.8 million...
Press Releases

Global Alzheimer’s Platform Foundation Commends Biogen and Eisai On Positive Aducanumab Findings

October 22, 2019
First disease-modifying drug in 16 years to be submitted for FDA approval in 2020 ***John Dwyer is available for comment today live from the National Alzheimer's Summit in Washington, D.C.***  Washington, DC (October 22, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement on the announcement today by Biogen and Eisai that a new analysis of a larger dataset from clinical studies...
Blog

Determined to End Alzheimer’s Disease: A Global Epidemic

October 1, 2019
The fight against a global epidemic September is a key month in the fight against Alzheimer’s and other dementias. Driven by Alzheimer’s Disease International, September has been designated as World Alzheimer's Month with World Alzheimer's Day on September 21 to prompt organizations worldwide to raise awareness and challenge the stigma that surround dementia. Global efforts are vital as people of varying races and ethnicities have different levels of risk. These worldwide...
In the News

Sharpton Blends Civil Rights Struggle with Disparaging Access to Health Care

September 26, 2019
Al Sharpton delivered the keynote address for the Black Health Care Coalition, speaking out against the health care of black people and specifically Alzheimer’s. Turning his attention to the upcoming 2020 election, Sharpton says “All of the candidates running for President of the United States have health plans and should be focusing to eliminate the disparity that causes minorities to face more challenges. There is more we can do in...
In the News

Alzheimer’s impact is a societal and economic issue, health advocate says

September 20, 2019
USAgainstAlzheimer’s chairman and co-founder George Vradenburg discusses the emotional and economic toll Alzheimer’s has on society as a whole and criticizes that lack of urgency by our political leaders in their willingness to address this health crisis. “The cost of dementia to the world today exceeds 1 percent of total global economic activity.  In the United States, the cost of dementia will be comparable to the defense budget in the...
Press Releases

Spartan Bioscience Partners with the Global Alzheimer’s Platform Foundation to Accelerate Alzheimer’s Research

July 31, 2019
Ottawa, Canada – Spartan Bioscience announced a partnership with the Global Alzheimer’s Platform Foundation® (GAP) to help recruit possible study participants and accelerate Alzheimer’s clinical trials. Through the partnership, Spartan will donate $5 from each sale of its rapid Apolipoprotein E (APOE) genetic pre-screening test to the GAP Transportation Program, which is powered by Lyft. GAP and Spartan are both seeking ways to improve enrollment in Alzheimer’s clinical trials. To...
In the News

Volunteers needed for Northeast Ohio Alzheimer’s disease clinical trials

July 22, 2019
The Brain Health and Memory Center in the Neurological Institute at University Hospitals Cleveland Medical Center honored its Alzheimer's clinical trials participants at a Citizen Scientist Awards ceremony in May. The UH Cleveland Medical Center is currently looking for additional trial participants. Read more from Mike Peticca in the Cleveland Plain Dealer here.
In the News

Two RSF Research and Innovation Center patients honored as Citizen Scientist Award nominees

July 10, 2019
Two Alzheimer's research participants from GAP-Net site Roper St. Francis Research and Innovation Center in Charleston, SC were honored as Citizen Scientists. Read more about the nominees' stories in Vital Signs.
In the News

Advocate recognizes Alzheimer’s patients, care partners

June 25, 2019
The Advocate Memory Center at Advocate Lutheran General Hospital in Park Ridge, IL recognized its inaugural Citizen Scientist Awards nominees and their care partners at a special awards ceremony. Read more in the Chicago Daily Herald here.
In the News

Alzheimer’s patients saluted for dedication to drug trials

June 20, 2019
GAP-Net site Okanagan Clinical Trials in Kelowna, BC recognized three of its Citizen Scientist Awards nominees in a ceremony at the Okanagan Innovation Centre in downtown Kelowna. Read more about the nominees in the Kelowna Daily Courier.
Press Releases

Global Alzheimer’s Platform Foundation Honors More Than 100 Clinical Trial Participants During National Citizen Scientist Week.

June 17, 2019
Washington, DC  – June 17-21, 2019 is the first ever National Citizen Scientist Week, a time to honor people who volunteer for Alzheimer’s research and inspire hope for new therapies for the disease. To celebrate the contributions of the remarkable volunteers who are participating in Alzheimer’s clinical trials, the Global Alzheimer’s Platform Foundation (GAP) is recognizing more than 100 Citizen Scientist® research participants nominated from its 73 affiliated Alzheimer’s research...
In the News

Alzheimer’s disease: Risk factors, treatments and more

June 13, 2019
A podcast discussing Alzheimer’s disease – research, risk prevention, and other related topics. Robert Herriman is joined by Phil Sabel, M.A., the Clinical Research Coordinator at GAP-Net site Axiom Clinical Research in Tampa. Click here to listen.
In the News

Is an Alzheimer’s Cure on the Horizon?

June 1, 2019
While Alzheimer’s is better understood today than in the past, no effective treatments for the disease have yet been found. One major challenge facing Alzheimer’s drug trials is finding participants. As GAP President John Dwyer says, “The biggest problem is that people are not aware of clinical trials. The fact is, the first person to be cured of Alzheimer’s will be in a clinical trial. It won’t randomly happen.” Read...
In the News

8 ways to reduce your risk of Alzheimer’s (and maybe help researchers find a cure faster)

May 26, 2019
The Acti-v8 Your Brain initiative provides eight ways in which people can make positive lifestyle changes to improve their brain health. This article puts special focus on pillar #8 (participating in Alzheimer’s clinical trials). Read the full story here.
Press Releases

Global Alzheimer’s Platform Foundation Commends National Institute on Aging for Advancing Its 2025 Goal by Funding a Diversified Portfolio of Studies

May 20, 2019
Washington, DC  – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: ““The nearly six million Americans with Alzheimer’s and their families deserve for no scientific stone to go unturned in the search for a cure. The Global Alzheimer’s Platform Foundation commends the National Institute on Aging for funding an expanded portfolio of later stage clinical trials. There is a large group of...
In the News

Dr. Anna Burke named 2019 Healthcare Innovator of the Year

May 3, 2019
AzBusiness recognized Dr. Anna Burke as its 2019 Healthcare Innovator of the Year for her work in treating the behavioral and psychiatric disturbances that result from Alzheimer’s disease as well as her work building a community outreach program in the Phoenix area to teach people about brain health, Alzheimer’s, and clinical research. Dr. Burke is a geriatric psychiatrist and director of neuropsychiatry at GAP-Net site Barrow Neurological Institute in Phoenix....
In the News

When It Comes to Alzheimer’s, Important Changes Are Coming for MA Beneficiaries

April 19, 2019
In a joint op-ed with George Vradenburg, co-founder of UsAgainstAlzheimer’s, GAP President John Dwyer argues that the Centers for Medicare and Medicaid Services (CMS) has taken an important first step towards improving our health care system’s ability to address Alzheimer’s. By authorizing significant payments for Medicare Advantage beneficiaries with a diagnosis of dementia, CMS has created a powerful financial incentive for early assessment and diagnosis of dementia. Read the full...
Press Releases

Global Alzheimer’s Platform Foundation Commends Commissioner Seema Verma and CMS for New Medicare Advantage Benefits and Payment Policies That Will Improve the Care Of Beneficiaries At Risk For Alzheimer’s and Related Dementias

April 10, 2019
Washington, DC  – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The Global Alzheimer’s Platform Foundation thanks Commissioner Seema Verma and the Centers for Medicare and Medicaid Services (CMS) for its thoughtful and impactful leadership in implementing policies that will improve Medicare Advantage beneficiaries’ ability to maintain their memory fitness by expanding supplemental benefits programs that will support memory fitness and brain...
In the News

Alzheimer’s Disease Trials: Where Do We Go From Here?

April 9, 2019
While the Alzheimer’s clinical trials field has seen setbacks recently in studies targeting the elimination of amyloid beta plaques, GAP is pressing full speed ahead towards an Alzheimer’s cure by accelerating current trials, streamlining the trial startup process, and boosting trial recruitment efforts. Read the full story here.
In the News

Ryan Grad Working to Speed Research into Alzheimer’s Cure

March 22, 2019
Nashville’s largest Catholic newspaper profiled John Dwyer, president of GAP and 1974 graduate of Father Ryan High School, a Catholic school in Nashville. The article covers GAP’s initiatives and quotes Linda Schipani, president and CEO for Clinical Research Associates in Nashville (a GAP-Net site). Read the full article here.
In the News

In Year Three, GAP Trial Network Is Starting to Hum

March 21, 2019
This two-part feature covers the 2019 GAP-Net Site Optimization Conference and the many ways in which GAP is bringing its patient-centered, business-oriented approach to improve Alzheimer’s clinical trials. Representatives from several GAP-Net sites are quoted and mentioned in the piece, which details GAP’s effort to boost recruitment and unclog procedural bottlenecks, as well as its partnership with Lyft aimed at making it easier for volunteers to access clinical trials. Read...
In the News

Addressing the GAPs in Alzheimer’s Trials, Treatment

March 12, 2019
In addition to covering the GAP-Net Site Optimization Conference, which took place in Nashville February 27 – March 1, the Nashville Medical News highlighted GAP’s efforts to speed and improve Alzheimer’s clinical trials through better administrative practices, a common IRB, and other disruptive tactics. The piece highlights two GAP-Net sites in Nashville: Clinical Research Associates and the Center for Cognitive Medicine at Vanderbilt University Medical Center. Read the full article here.
In the News

Boosting Alzheimer’s trial participation via Medicare Advantage “memory fitness programs”

March 11, 2019
This Clinical Neurology News story discusses GAP’s efforts to support and collaborate with “memory fitness programs” through select Medicare Advantage plans to encourage higher participation in Alzheimer’s clinical trials. Read the full story here.
Press Releases

GAP Foundation Unveils Roadmap for Increasing Participation in Alzheimer’s Research

February 28, 2019
GAP President Calls Memory Fitness Programs Through Medicare Advantage “a Game-Changer” Nashville – Global Alzheimer’s Platform Foundation (GAP) President John Dwyer today announced a roadmap for increasing participation in Alzheimer’s clinical trials by supporting and collaborating with memory fitness supplemental benefit programs offered through select Medicare Advantage plans across the United States. Dwyer made the announcement in a speech to more than 150 experts on Alzheimer’s clinical trials from GAP’s network...
Press Releases

Leading Alzheimer’s Researchers Coming to Nashville for GAP-Net Site Optimization Conference

February 27, 2019
Researchers, recruiters, and CEOs from more than 70 Alzheimer’s clinical trial sites to share strategies on finding a cure for the deadly disease From February 27 – March 1, the Global Alzheimer’s Platform Foundation (GAP), an organization dedicated to speeding and improving Alzheimer’s clinical trials in pursuit of a cure, will convene more than 150 representatives from its network (GAP-Net) of 70+ Alzheimer’s clinical research sites at the Nashville Marriott at...
In the News

A cure for Alzheimer’s is not possible without you

February 26, 2019
GAP President John Dwyer and Dr. Paul Newhouse, director of the GAP-Net site Center for Cognitive Medicine at Vanderbilt University Medical Center (VUMC), published an op-ed speaking to the importance of clinical trial participation in the fight to end Alzheimer’s. The piece, which highlights VUMC’s Alzheimer’s clinical trials, ran just before the 2nd annual GAP-Net Site Optimization Conference in Nashville, which gathered GAP-Net researchers and clinical trial recruiters, CEOs, clinical trial sponsors,...
Press Releases

Barrow Receives $100,000 Grant for Alzheimer’s Program

February 19, 2019
Global Alzheimer’s Platform Foundation recognizes strong, expanding research WASHINGTON, DC (February 19, 2019) – The Global Alzheimer’s Platform Foundation (GAP) announced a $100,000 grant to the Barrow Neurological Foundation to optimize and support the Alzheimer’s clinical trials program at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center. The grant will go toward participant retention efforts, staff education programs, improving productivity and building a database for clinical trial...
Press Releases

$90,000 GAP Grant to Toronto Memory Program Funds Alzheimer’s Education & Outreach

January 22, 2019
Grant Funds January 28 Community Event at Ontario Science Centre and Expanded Clinical Trial Education Programs TORONTO -The Global Alzheimer’s Platform Foundation and Toronto Memory Program have initiated a multi-faceted project to educate the Ontario community about Alzheimer’s disease, brain health and the role of Alzheimer’s clinical trials. Toronto Memory Program is a member of the GAP-Net network of 70 prominent research sites working with the nonprofit Global Alzheimer’s Platform Foundation to speed and improve...
Press Releases

Chicago Event to Encourage Participation in Alzheimer’s Clinical Research

November 2, 2018
Event is on November 8, Chicago Alzheimer’s Awareness DayWASHINGTON, D.C. – On November 8th – Chicago Alzheimer’s Awareness Day – Great Lakes Clinical Trials and the Global Alzheimer’s Platform Foundation are hosting a major community event for people in the community who are interested in learning more about memory concerns and Alzheimer’s disease. Research volunteers, including care partners, are being honored and celebrated, and will share their personal stories and motivation for volunteering. People from...
Press Releases

Statement from Global Alzheimer’s Platform (GAP) Foundation on the National Strategy for Recruitment and Participation in Alzheimer’s Disease Clinical Research

October 19, 2018
WASHINGTON, D.C. – “I would like to thank the National Institute on Aging for its thoughtful work on the national strategy. More effective recruitment means faster trials and getting approved therapies to market years sooner. The Global Alzheimer’s Platform Foundation is pleased to join in this effort by building a better research infrastructure through GAP-NET, its network of leading academic and private research centers; forging partnerships with healthcare professionals to increase...
Press Releases

Global Alzheimer’s Platform Foundation Launches Citizen Scientist Awards®, A National Initiative Celebrating Clinical Trial Participants

September 25, 2018
WASHINGTON, D.C. – More than 5.7 million Americans suffer from Alzheimer’s disease and researchers rely upon clinical trial volunteers to be the first step towards a cure. The Global Alzheimer’s Platform Foundation (GAP) has launched the Citizen Scientist Awards®, the first national awards program recognizing and celebrating Alzheimer’s disease clinical trial participants. The awards are designed to broaden awareness of the benefits of clinical research for current and future generations and increase...
In the News

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough

June 22, 2018
Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough The search for a drug to treat Alzheimer’s disease, the most common form of dementia, has been marked by clinical trial failures.A new report from top researchers says the number of drugs advancing through clinical phase two and phase three trials provides reason to believe that breakthroughs may be in the current pharmaceutical pipeline.The...
In the News

How a Raleigh clinic is helping Alzheimer’s patients

April 13, 2018
Alzheimer’s clinical trial participants are getting a lift to their appointments at Raleigh Neurology Associates. The Global Alzheimer’s Platform Foundation, in partnership with Lyft, is providing transportation to participants in an Eli Lilly study testing a therapy to attack plaque in the brain characteristic of Alzheimer’s disease. Sean Walsh, director of clinical research at Raleigh Neurology Associates, says the new partnership will help the patient experience and increase efficiency and lower costs. Raleigh Neurology is one of 15...
Press Releases

Global Alzheimer’s Platform (GAP) Foundation Launches Partnership with Lyft to Transport Clinical Trial Participants to and from Clinical Research Facilities Across North America

March 20, 2018
WASHINGTON, D.C. – The Global Alzheimer’s Platform Foundation has launched a partnership with Lyft to provide transportation for Alzheimer’s clinical trial participants to and from research sites. The partnership began on Feb. 20 with a pilot in California. Transportation will be available for participants and care partners who are part of Eli Lilly and Company’s (Lilly) study TRAILBLAZER-ALZ, an Alzheimer’s disease clinical trial testing a combination therapy designed to attack amyloid plaque, one of the key...
Press Releases

Statement from Global Alzheimer’s Platform (GAP) Foundation in Response to Bill Gates’ Investment in Alzheimer’s Research

November 13, 2017
WASHINGTON, D.C. – “The Global Alzheimer’s Platform Foundation (GAP) enthusiastically welcomes Bill Gates and his team to the fight against Alzheimer’s disease. This epidemic, which affects millions of people worldwide, is growing exponentially and requires new thinking and investment to begin to stem that tide. We at Global Alzheimer’s Platform Foundation are focused on disrupting the Alzheimer’s clinical trial system by collaborating with our 59 (and growing) GAP-Net research sites to reduce time-to-trial by...
In the News

Can GAP double the number of patients in Alzheimer’s trials?

Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than 30 percent of total trial time is spent simply recruiting patients. Those issues are present...
In the News

Minority participation in clinical trials can help everyone fight Alzheimer’s

November 6, 2017
Growing up as an African-American in the South over 75 years ago, my family didn’t have the access to medical care we do today. One event from my childhood changed my life. My mother went to the doctor’s office. She was quite ill and needed help. The doctor said she had to wait to be seen until after all of the white patients were assisted. It was at that moment...
Press Releases

Global Alzheimer’s Platform (GAP) Foundation Unites 58 of the World’s Leading Research Sites With Goal of Doubling Clinical Trial Participation in USA

November 1, 2017
More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked SitesKansas City Pilot Program Increased Volunteer Trial Participation by 292% WASHINGTON, D.C. – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone.  It is projected that 14 million people in the U.S. will be afflicted with Alzheimer’s disease by 2050. The Global...
In the News

Patient advocacy groups welcome 40% increase in Alzheimer’s NIH research funds authorized by Congress

May 9, 2017
The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), a Washington-based entity launched in 2015 by UsAgainstAlzheimer’s and the Global CEO Initiative (CEOi) on Alzheimer’s Disease. GAP works with leading...
Press Releases

Global Alzheimer’s Platform Foundation Supports $400 Million Congressional Increase for Alzheimer’s Research Funding

May 4, 2017
Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost WASHINGTON, D.C. – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National Institutes of Health (NIH) will receive a $2 billion boost in fiscal year 2017, as it did the previous year. The NIH budget continues to support...
In the News

Hope to prevent Alzheimer’s? Grab the olive oil and hop on a treadmill

November 26, 2016
Ann Poehler’s strides quicken on the treadmill. Her feet pound. Her heart races from 150 to 160 beats per minute and more. A plastic tube jutting from the Prairie Village woman’s mouth feeds carbon dioxide levels to a computer here inside the University of Kansas Alzheimer’s Disease Center. The computer records every respiration while an exercise physiologist coaches her to push harder. “Can you hang in there like for 15 more...
Press Releases

Global Alzheimer’s Platform Foundation Appoints Pascale Witz to Board of Directors

September 15, 2016
Pascale Witz brings two decades of healthcare leadership experience to GAP Board WASHINGTON, D.C. (Sep. 15, 2016) – Global Alzheimer’s Platform Foundation, Inc. (GAP), a nonprofit organization dedicated to reducing the duration, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Pascale Witz to its Board of Directors. In this role, Pascale will provide counsel based on her vast experience working as a healthcare executive with leading healthcare...
In the News

National survey finds that a majority of Americans would consider participating in an Alzheimer’s clinical trial

August 1, 2016
A recent online survey conducted by Harris Poll found that nearly 60% of Americans are definitely willing or willing to consider taking part in a clinical trial for Alzheimer’s. This promising statistic is good news for researchers; however, obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the ground. To address this, the Global Alzheimer’s Platform Foundation commissioned a survey to examine Americans’...
Press Releases

Global Alzheimer’s Platform Foundation Announces GAP-Net

July 28, 2016
First-of-its-Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials WASHINGTON, D.C. – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP-Net, a first-of-its-kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP-Net currently has 11 leading academic and private commercial research site partners. The network looks to add a minimum of 20 more sites by year-end and grow...
Press Releases

Global Alzheimer’s Platform Foundation Appoints Dr. Kate Zhong as Chief Strategy Officer

July 27, 2016
Dr. Zhong Brings More Than 20 Years of Experience to Organization’s New Role WASHINGTON, D.C. – Global Alzheimer’s Platform Foundation (GAP), a nonprofit organization dedicated to reducing the time, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Dr. Kate Zhong to the new position of Chief Strategy Officer (CSO). In this role, Dr. Zhong will lead strategic development advancing GAP’s efforts to disrupt the inefficient clinical trial system with...
Press Releases

Majority Of Americans Would Consider Participating In An Alzheimer’s Clinical Trial. So, Why Are Enrollment Numbers So Low?

July 18, 2016
Global Alzheimer’s Platform (GAP) Foundation is promoting innovative and easier-to-use clinical trial participation tools, including the Brain Health Registry WASHINGTON, D.C. – In a first-ever poll conducted online by Harris Poll on behalf of the Global Alzheimer’s Platform (GAP) Foundation, nearly 60% of Americans report they are definitely willing or would consider participating in Alzheimer’s disease clinical trials, but participation rates show that less than 10% are actually doing so (source)....